

Precision Oncology and Integrative Medicine – contradiction or synergy?

DR NINA FULLER-SHAVEL

MB BCHIR MA HONS (CANTAB) IFMCP DIPIM PG CERT DIPION RYT200

DIRECTOR OF SYNTHESIS CLINIC, CO-CHAIR BRITISH SOCIETY FOR INTEGRATIVE ONCOLOGY, FELLOW OF THE COLLEGE OF MEDICINE



Introduction – Dr Nina Fuller-Shavel

- Degrees in Natural Sciences and Medicine from the University of Cambridge
 - Background in cellular and molecular biology, distinction in Pathology, winner of the Henry Roy Dean Prize
- Postgraduate degrees in nutrition and integrative medicine and additional qualifications in herbal medicine, yoga and mindfulness
- Fellow of the College of Medicine
- Co-Chair of the British Society for Integrative Oncology
- Director of Synthesis Clinic (UK) an award-winning multidisciplinary integrative medicine practice specialising in women's health and integrative cancer support for solid tumours with a specialist interest in breast and gynaecological cancers (in collaboration with oncology teams)
- Research interests in precision cancer medicine (MSc University of Oxford) and integrative cancer support
 - Member of the conference committee for ECIM 2021 and reviewer for integrative oncology abstracts
- Educator training for medical and nutrition professionals in integrative medicine for women's health and integrative oncology (systems approach to cancer)

Session outline

- Review what integrative medicine and integrative oncology is
- Why does it matter?
- Thinking about the intersection with precision oncology contradiction or synergy?

Integrative oncology

Integrative oncology definitions

- Integration of evidence-informed conventional, psychological, nutritional, lifestyle and complementary medicine in cancer care to support better quality of life, improve resilience, minimise the side effects of treatment and improve outcomes (BSIO definition)
- Integrative oncology is a patient-centered, evidence-informed field of cancer care that utilizes mind and body practices, natural products, and/or lifestyle modifications from different traditions alongside conventional cancer treatments. Integrative oncology aims to optimize health, quality of life, and clinical outcomes across the cancer care continuum and to empower people to prevent cancer and become active participants before, during, and beyond cancer treatment." (Claudia Witt and SIO team)



Why bother?

> Your patients are already doing it!

- Based on various sources and variation based on location, between 40% and 90% of cancer patients use complementary medicine
 - Average likely around 50%
 - ► Australian range 17% to 87% of cancer patients
 - Demographics younger, female, having higher education, earning a higher income and having previously used CAM
- Saying 'no' to everything means hidden risk and internal conflict for the patient, it does not mean compliance
 - Safe integrative oncology being open and honest (mutual), ensuring appropriately qualified and experienced practitioners are on the case, ideally regular interprofessional communication



What does integrative oncology have to offer?

- A sense of agency and empowerment for your patients
 - Supporting resilience vs learned helplessness
- Expanded toolkit to support:
 - Cancer prevention
 - Pre-habilitation for better treatment tolerance and recovery
 - Managing side effects of treatment and opportunities for improving outcomes
 - Faster recovery following active treatment and better management of recurrence risk
 - Care of patients with metastatic disease both in living well with cancer and at the end of life

Integrative oncology

Is/should be:

- a rational and personalised integration of the best in conventional, psychological, lifestyle and complementary medicine
- whole-person oriented and addresses physical, emotional, mental and spiritual needs
- supportive of targeted, personalised medication use where necessary without over-medicalising
- about caring for people, not mindless protocols
- evidence-based medicine combining the best available research evidence, clinical expertise and patient values

Integrative oncology consultation				
Lifestyle management	Herb and supplement consultation			
 Nutrition and diet Physical activity and exercise Sleep hygiene Stress management 	 Assess and address CAM expectations Evaluate safety and potential herb-drug interactions Discuss evidence and advise on appropriate 			

Symptom	Pain	Fatigue	Insomnia	Anxiety	
Modality	• Acupuncture ³⁰ • Massage ³³⁻³⁵ • Meditation ⁶¹⁻⁶⁴	• Exercise ¹⁴⁻¹⁶ • Yoga ^{7,47} • Acupuncture ^{30,32}	• CBT-I ^{22,23} • Yoga ^{7,47} • Tai chi ^{7,25}	• Meditation ¹⁰ • Yoga ¹⁰ • Massage ^{34,35}	
Symptom	Nausea and vomiting	Neuropathy	Dry mouth	Hot flashes	
Modality	• Acupuncture ¹⁰ • Acupressure ¹⁰	• Acupuncture ³⁰ • Massage ⁶⁵	• Acupuncture ³⁰	• Acupuncture ³⁰ • Hypnosis ⁶⁶ • Yoga ^{67,68}	

Integrative medicine for symptom control

 Discuss evidence and advise on appropriate herb or supplement use in the cancer setting Example of integrative oncology framework

Our clinic team and referrals

Lead medical doctor with supporting team

- Individualised assessment including clinical history +/- examination, oncology imaging, test results and review of plan; additional testing as appropriate (liquid biopsies, specialised blood tests)
- Personalised plan based on therapeutic aims/stages and patient needs and goals medication review; lifestyle as core (nutrition, physical activity, sleep and stress management/psychoemotional wellbeing); additional targeted support (checked for interactions) +/- referral for other therapies
- Regular monitoring symptom/QOL scores, blood tests
- Nutrition team
- Cancer exercise specialist referrals
- Physiotherapy, rehabilitation Pilates and ScarWork in-house
- Emotional wellbeing coaching
 - Referrals for psychology +/- trauma therapy as appropriate
- Referrals for specific therapies, e.g. acupuncture during chemotherapy re: N&V and CIPN etc

Care pathway



Medical assessment and integrative care plan, including baseline bloods Lifestyle advice (nutrition, physical activity, stress management and sleep) supported by appropriate professionals

Additional personalised intervention as appropriate Repeat medical review with feedback from the multidisciplinary team, repeat biomarkers + review of symptom/QOL tracking data; medication review as necessary

Integrative Oncology and Precision Oncology

How can this help within precision oncology?

- Managing side effects from targeted therapies
- Improving outcomes, managing MDR and potential treatment synergy
 - Immunotherapy and the gut microbiome minimising antibiotic use, supporting *Bifidobacteria* and *Akkermansia* levels (FMT being extensively studied but accessibility is an issue, dietary/nutraceutical modulation is far more widely applicable)
 - Specific targets that do not yet have a pharmaceutical allocation (potential benefit, requires more research but review risk-benefit)



Managing side effects – example

- Lapatinib and fasting compared to bedtime administration, lapatinib administration after overnight fasting may reduce its toxicity without diminishing its therapeutic efficacy.
 - > 140 breast cancer patients enrolled in the JBCRG-16/Neo-LaTH randomized phase 2 trial
 - A reduced risk of diarrhoea {adjusted hazard ratio (HR), 0.51, 95% confidence interval (CI), 0.27-0.89, p = 0.018}, and rash {adjusted HR, 0.37; 95% CI, 0.17-0.70, p = 0.002} was seen in BB (before breakfast) versus AB (at bedtime)
 - Itreatment synergy animal studies show that fasting increases the ability of common TKIs, including erlotinib, gefitinib, lapatinib, crizotinib and regorafenib, to block cancer cell growth, to inhibit MAPK signalling pathway and to strengthen E2F-dependent transcription inhibition

Tsuda M, Ishiguro H, Toriguchi N, Masuda N, Bando H, Ohgami M, Homma M, Morita S, Yamamoto N, Kuroi K, Yanagita Y, Takano T, Shimizu S, Toi M. Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. Cancer Med. 2020 Dec;9(24):9246-9255

Managing side effects – PI3K inhibitors and metabolic compromise

- Hyperglycemia is a common, on-target adverse effect that impairs treatment efficacy and increases the rate of treatment delays, dose reductions, and discontinuation
- ▶ When metformin is not effective, VLCD and SGLT2i may be effective early data

Example of treatment synergy (chemotherapy)

Curcumin and FOLFOX for CRC

Phase IIa open label RCT – 28 metastatic CRC patients randomised to FOLFOX compared with FOLFOX + 2 g oral curcumin/d (CUFOX) - HR for PFS was 0.57 (95% CI: 0.24, 1.36; P = 0.2) (median of 171 and 291 d for FOLFOX and CUFOX, respectively) and for OS was 0.34 (95% CI: 0.14, 0.82; P = 0.02) (median of 200 and 502 d for FOLFOX and CUFOX, respectively). There was no significant difference between arms for quality of life (P = 0.248) or neurotoxicity (P = 0.223).

Howells LM, Iwuji COO, Irving GRB, Barber S, Walter H, Sidat Z, Griffin-Teall N, Singh R, Foreman N, Patel SR, Morgan B, Steward WP, Gescher A, Thomas AL, Brown K. Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. J Nutr. 2019 Jul 1;149(7):1133-1139.



Integrative oncology and MDR

- Curcumin as modulator of P-gp by inhibiting both P-gp function and expression but issues with bioavailability and stability (products have been created with better profiles)
 - Nanoparticle approaches being studied, e.g. curcumin and paclitaxel
- > Other natural compounds being studied, e.g. resveratrol, quercetin

Potential for precise targeting – some early ideas and examples for further research

► TYMS upregulation

- High dose melatonin (20-60mg) may be useful early cell evidence, clinical evidence accumulating
- Quercetin/curcumin and Wnt/beta-catenin
- Multitarget effects of certain key substances
 - Curcumin may exert therapeutic effects via regulating miRNA expression (e.g., miR-1, miR-7, miR-9, miR-34a, miR-181, miR-21, and miR-19) which could lead to the regulation of underlying cellular and molecular pathways involved in cancer pathogenesis.
 - Quercetin could modulate multiple cancer-relevant miRNAs including let-7, miR-21, miR-146a and miR-155; quercetin modulates PI3K/Akt/mTOR, Wnt/beta-catenin, and MAPK/ERK1/2 pathway
 - > And many more (curcumin, resveratrol, berberine and quercetin being some of the most common studied)
- Synergistic effects are possible, e.g. ginkgetin and resveratrol in suppressing VEGF-induced angiogenesis (animal work)

Growth factor receptor protein tyrosine:

Epidermal growth factor receptor tyrosine phosphorylation ↓ Epidermal growth factor receptor Kinase activity ↓ Protein tyrosine Kinase of epidermal growth receptor and p185neu ↓

Growth and metastases genes:

COX-2 and lipoxygenase↓ Cyclin D 1↓ Tumor suppressor gene p53↑ CDK4-mediated retinoblastoma protein phosphorylation↓ MMP-9 and MMP-2↓


Curcumin anticancer activity

Transcription factors:


 $NF-\kappa B \downarrow$, STAT (1,3,4 and 5) \downarrow , β -Catenin \downarrow , PPAR- $\gamma\uparrow$, AP-1 \downarrow (through inhibition of JNK and fos-jun DNA complex) Inflammatory cytokines and multiple kinases:

TNF-α↓, Interlukin, IL-1,2,5,6,8,12 and 18↓ Serine or threonine protein kinases (PhK, protein kinase A & B, protamine kinase cPK, AK)↓ Mitogen activated protein kinase↓ Pyruvate kinase M2 (PKM2)↓

Curcumin




Wnt targeting pathway overview




Hitting the hallmarks

Integrative oncology for maximizing effects and minimizing toxicity


Summary



- Appropriate use of evidence-informed lifestyle and complementary interventions can be of significant benefit in relieving side effects and improving tolerance of treatment, ideally as a part of integrative care plans.
 - > True integration and alignment in purpose and the components of the management plan is essential
- More evidence is needed to assess the optimal timing and combination of interventions (including interaction with targets identified with precision oncology approaches and management of MDR) and to monitor impact on biomarkers and clinical outcomes
 - Multidisciplinary research teams with oncology, integrative medicine/nutrition/phytochemistry experts and laboratory scientists - rational project selection, interaction checking and appropriate outcome measures and biomarkers



- Costea T, Vlad OC, Miclea LC, Ganea C, Szöllősi J, Mocanu MM. Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer. Int J Mol Sci. 2020 Jan 8;21(2):401. doi: 10.3390/ijms21020401. PMID: 31936346; PMCID: PMC7013436.
- Jones E, Nissen L, McCarthy A, Steadman K, Windsor C. Exploring the Use of Complementary and Alternative Medicine in Cancer Patients. Integr Cancer Ther. 2019 Jan-Dec;18:1534735419846986. doi: 10.1177/1534735419846986. PMID: 31072149; PMCID: PMC7242794.
- Howells LM, Iwuji COO, Irving GRB, Barber S, Walter H, Sidat Z, Griffin-Teall N, Singh R, Foreman N, Patel SR, Morgan B, Steward WP, Gescher A, Thomas AL, Brown K. Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. J Nutr. 2019 Jul 1;149(7):1133-1139. doi: 10.1093/jn/nxz029. PMID: 31132111; PMCID: PMC6602900.



- Keene MR, Heslop IM, Sabesan SS, Glass BD. Complementary and alternative medicine use in cancer: A systematic review. Complement Ther Clin Pract. 2019 May;35:33-47. doi: 10.1016/j.ctcp.2019.01.004. Epub 2019 Jan 11. PMID: 31003679.
- Khan MAW, Ologun G, Arora R, McQuade JL, Wargo JA. Gut Microbiome Modulates Response to Cancer Immunotherapy. Dig Dis Sci. 2020 Mar;65(3):885-896. doi: 10.1007/s10620-020-06111-x. PMID: 32067144; PMCID: PMC7678709.
- Kim DH, Khan H, Ullah H, Hassan STS, Šmejkal K, Efferth T, Mahomoodally MF, Xu S, Habtemariam S, Filosa R, Lagoa R, Rengasamy KR. MicroRNA targeting by quercetin in cancer treatment and chemoprotection. Pharmacol Res. 2019 Sep;147:104346. doi: 10.1016/j.phrs.2019.104346. Epub 2019 Jul 8. PMID: 31295570.
- Latte-Naor S, Mao JJ. Putting Integrative Oncology Into Practice: Concepts and Approaches. J Oncol Pract. 2019 Jan;15(1):7-14. doi: 10.1200/JOP.18.00554. PMID: 30629900; PMCID: PMC6333385.

- Lopes-Rodrigues V, Sousa E, Vasconcelos MH. Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives. Pharmaceuticals (Basel). 2016 Nov 10;9(4):71. doi: 10.3390/ph9040071. PMID: 27834897; PMCID: PMC5198046.
- Mirzaei H, Masoudifar A, Sahebkar A, Zare N, Sadri Nahand J, Rashidi B, Mehrabian E, Mohammadi M, Mirzaei HR, Jaafari MR. MicroRNA: A novel target of curcumin in cancer therapy. J Cell Physiol. 2018 Apr;233(4):3004-3015. doi: 10.1002/jcp.26055. Epub 2017 Aug 3. PMID: 28617957.
- Reyes-Farias M, Carrasco-Pozo C. The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism. Int J Mol Sci. 2019 Jun 28;20(13):3177. doi: 10.3390/ijms20133177. PMID: 31261749; PMCID: PMC6651418.
- Sakatani A, Sonohara F, Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. Carcinogenesis. 2019 May 14;40(3):422-431. doi: 10.1093/carcin/bgy186. PMID: 30590435; PMCID: PMC6514450.
- Sferrazza G, Corti M, Brusotti G, Pierimarchi P, Temporini C, Serafino A, Calleri E. Nature-derived compounds modulating Wnt/β-catenin pathway: a preventive and therapeutic opportunity in neoplastic diseases. Acta Pharm Sin B. 2020 Oct;10(10):1814-1834. doi: 10.1016/j.apsb.2019.12.019. Epub 2020 Jan 7. PMID: 33163337; PMCID: PMC7606110.

- Tomeh MA, Hadianamrei R, Zhao X. A Review of Curcumin and Its Derivatives as Anticancer Agents. Int J Mol Sci. 2019 Feb 27;20(5):1033. doi: 10.3390/ijms20051033. PMID: 30818786; PMCID: PMC6429287.
- Tsuda M, Ishiguro H, Toriguchi N, Masuda N, Bando H, Ohgami M, Homma M, Morita S, Yamamoto N, Kuroi K, Yanagita Y, Takano T, Shimizu S, Toi M. Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. Cancer Med. 2020 Dec;9(24):9246-9255. doi: 10.1002/cam4.3528. Epub 2020 Oct 23. PMID: 33094919; PMCID: PMC7774723.
- Witt CM, Balneaves LG, Cardoso MJ, Cohen L, Greenlee H, Johnstone P, Kücük Ö, Mailman J, Mao JJ. A Comprehensive Definition for Integrative Oncology. J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52). doi: 10.1093/jncimonographs/lgx012. PMID: 29140493.
- Zhao MD, Li JQ, Chen FY, Dong W, Wen LJ, Fei WD, Zhang X, Yang PL, Zhang XM, Zheng CH. Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer. Int J Nanomedicine. 2019 Dec 2;14:9453-9467. doi: 10.2147/IJN.S224579. PMID: 31819443; PMCID: PMC6898996.